Clinical Trials Browser

Mesothelioma, Malignant

Lung Neoplasms

Prostatic Neoplasms

Squamous Cell Carcinoma of Head and Neck, Breast Neoplasms, Carcinoma, Lymphoma, Lymphoma, Non-Hodgkin

Pancreatic Neoplasms

Squamous Cell Carcinoma of Head and Neck

Prostate Adenocarcinoma

Prostatic Neoplasms

Vulvar Neoplasms

Glioblastoma, Gliosarcoma

Esophageal Neoplasms

Esophageal Neoplasms

Glioblastoma, Gliosarcoma

Oropharyngeal Neoplasms

Carcinoma, Non-Small-Cell Lung

Neoplasm Metastasis, Hematologic Neoplasms

Glioblastoma, Recurrence

Prostatic Neoplasms

Colorectal Neoplasms

Melanoma, Sarcoma

Rectal Neoplasms

Sarcoma, Ewing

Stage I Prostate Adenocarcinoma AJCC v7

Carcinoma, Hepatocellular

Astrocytoma, Glioblastoma, Oligodendroglioma

Prostatic Neoplasms

Carcinoma, Oropharyngeal Neoplasms

Prostatic Neoplasms

Hodgkin Disease, Neoplasms

Breast Neoplasms

Neoplasm Metastasis, Prostatic Neoplasms

Brain Neoplasms

Lung Neoplasms

Biliary Tract Neoplasms, Carcinoma, Hepatocellular

Borderline Resectable Pancreatic Adenocarcinoma

Prostatic Neoplasms

Prostate Adenocarcinoma

Neoplasm Metastasis

Pancreatic Neoplasms

Urinary Bladder Neoplasms

Glioblastoma

Clinical Trials

Pembrolizumab After Radiation Therapy in Treating Patients With Pleural Malignant Mesothelioma

Characterizing Chemo-Radiotherapy Treatment-Related Cardiac Changes

Hypofractionated Radiation Therapy for Treating Prostate Cancer High-Risk Features Following Radical Prostatectomy

Vaccination With Flt3L, Radiation, and Poly-ICLC

NBTXR3 Activated by Radiation Therapy for the Treatment of Locally Advanced or Borderline-Resectable Pancreatic Cancer

Adjuvant Treatment Deintensification After Transoral Surgery for Human Papillomavirus-Positive Squamous Cell Carcinoma

Hypofractionated Radiation Therapy or Conventional Radiation Therapy After Surgery in Treating Patients With Prostate Cancer

Conventional or Hypofractionated Radiation Therapy in Treating Patients With Prostate Cancer

Nelfinavir, Cisplatin, and External Beam Radiation Therapy for the Treatment of Locally Advanced Vulvar Cancer That Cannot Be Removed by Surgery

Peposertib and Radiation Therapy, Followed by Temozolomide for the Treatment of Patients With Newly Diagnosed MGMT Unmethylated Glioblastoma or Gliosarcoma

Chemoradiation Plus Iparomlimab Consolidation in Older With ESCC

PIONEER

Testing the Addition of the Chemotherapy Drug Lomustine (Gleostine) to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Methylated Glioblastoma

ARTHOUSE

Pembrolizumab and Stereotactic Body Radiation Therapy or Non-Stereotactic Wide-Field Radiation Therapy in Treating Patients With Non-small Cell Lung Cancer

Salvage Radiation Therapy in Treating Patients With Metastatic Cancer That Has Progressed After Systemic Immunotherapy

GBM AGILE

Androgen Ablation Therapy With or Without Niraparib After Radiation Therapy for the Treatment of High-Risk Localized or Locally Advanced Prostate Cancer

Platform Study of Immunotherapy Combinations in Colorectal Cancer Liver Metastases

LauT1

Combining DCSZ11 With Radiation and Chemotherapy as Neoadjuvant Treatment for pMMR Locally Advanced Rectal Cancer

BEAR

SWISS-Pearl

Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by Surgery

Radiation Therapy With Protons or Photons in Treating Patients With Liver Cancer

Testing the Addition of an Anti-cancer Viral Gene Therapy, Toca 511/Toca FC, to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed Glioblastoma

Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer, INNOVATE Trial

Comparing Cisplatin Every Three Weeks to Cisplatin Weekly When Combined With Radiation for Patients With Advanced Head and Neck Cancer

Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer

Adcetris (Brentuximab Vedotin), Combination Chemotherapy, and Radiation Therapy in Treating Younger Patients With Stage IIB, IIIB and IV Hodgkin Lymphoma

Temporal Immunologic Changes With Hypofractionated Radiation-Induced DNA Damage in Breast Cancer

Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced Malignancies

RECARE

Safety and Efficacy of Radiotherapy Combined With Immunochemotherapy in Pre-treated SCLC Patients With Liver Metastases

Durvalumab (MEDI4736) and Tremelimumab and Radiation Therapy in Hepatocellular Carcinoma and Biliary Tract Cancer

New and Emerging Therapies for the Treatment of Resectable, Borderline Resectable, or Locally Advanced Pancreatic Cancer, PIONEER-Panc Study

Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial

Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial

Comparing Radiation Therapy to Usual Treatment for Patients With High-Risk Bone Metastases That Are Not Causing Pain, PREEMPT Trial

LAP100

Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study

Temporally-Modulated Pulsed Radiation Therapy Versus Standard Radiation Therapy for the Treatment of Newly Diagnosed, IDH Wildtype, MGMT-Unmethylated Glioblastoma